title: Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.
abstract: In a double-blind, parallel-group randomised trial of 3 months' duration, the efficacy of cyclandelate 800 mg twice daily in migraine prophylaxis was compared with that of flunarizine 5mg daily in 40 patients. In comparison with placebo and baseline values, both drugs significantly relieved symptoms of migraine as assessed by indices of pain total index, headache index, analgesic consumption and number of migraine days. Patients taking flunarizine experienced side effects such as drowsiness, weight gain and asthenia, while the most common complaint reported with cyclandelate was gastric upset. These results suggest that cyclandelate may be a useful alternative in migraine prophylaxis.
authors.forename: G
authors.initials: G
authors.lastname: Nappi
authors.forename: G
authors.initials: G
authors.lastname: Sandrini
authors.forename: G
authors.initials: G
authors.lastname: Savoini
authors.forename: A
authors.initials: A
authors.lastname: Cavallini
authors.forename: C
authors.initials: C
authors.lastname: de Rysky
authors.forename: G
authors.initials: G
authors.lastname: Micieli
mesh_terms: D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003495:Cyclandelate / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005444:Flunarizine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*; D011897:Random Allocation
chemical_list: D008333:Mandelic Acids; D003495:Cyclandelate; D005444:Flunarizine